{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Particle-Engineering Delivery Systems Showing Versatility for Antibiotic Delivery in Lung Diseases - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"nYnSJdK4IP\"><a href=\"https:\/\/themedicalxchange.com\/en\/2013\/06\/05\/american-thoracic-society-ats-2013-international-c\/\">Particle-Engineering Delivery Systems Showing Versatility for Antibiotic Delivery in Lung Diseases<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2013\/06\/05\/american-thoracic-society-ats-2013-international-c\/embed\/#?secret=nYnSJdK4IP\" width=\"600\" height=\"338\" title=\"&#8220;Particle-Engineering Delivery Systems Showing Versatility for Antibiotic Delivery in Lung Diseases&#8221; &#8212; The Medical Xchange\" data-secret=\"nYnSJdK4IP\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2013\/06\/EX_7006_ATS_EN_slide_.png","thumbnail_width":960,"thumbnail_height":720,"description":"Philadelphia \u2013 Particle engineering technology is coming of age for topical delivery of antibiotics to patients with chronic lung diseases, according to separate clinical trials presented at this year\u2019s American Thoracic Society (ATS) International Conference. In one study, the goal was to evaluate the efficacy and safety of delivering tobramycin in dry powder form to the lungs of children with cystic fibrosis (CF). In the other, lung deposition of dry powder inhaled (DPI) ciprofloxacin was measured in adults with chronic obstructive pulmonary disease (COPD). Both studies suggested that this technology is highly effective and safe for delivering therapeutic levels of topical antibiotics to lung tissue."}